Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDT | P30046 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | MALT1 | Q9UDY8 | 5/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4799754 | 0.90 | MAPK14 (0.37) | DDTMAPK14CNR2NR1I2TYK2 | |
| SCHEMBL4783259 | 0.88 | MAPK14 (0.34) | MAPK14NR1I2MALT1BRAF | |
| SCHEMBL4781726 | 0.85 | MAPK14 (0.41) | DDTMAPK14MALT1 | |
| SCHEMBL4781875 | 0.84 | SCN10A (0.34) | MAPK14NR1I2MALT1RAF1BRAF | |
| SCHEMBL4783784 | 0.83 | TEK (0.40) | DDTCNR2NR1I2RAF1BRAF | |
| SCHEMBL4783260 | 0.82 | MAPK14 (0.31) | MAPK14NR1I2RAF1BRAF | |
| SCHEMBL4781042 | 0.82 | BRAF (0.32) | MAPK14CNR2NR1I2RAF1BRAF | |
| SCHEMBL13843781 | 0.82 | APP (0.36) | DDTMAPK14NR1I2BRAF | |
| SCHEMBL4783359 | 0.82 | MAPK14 (0.35) | MAPK14NR1I2MALT1RAF1BRAF | |
| SCHEMBL4780945 | 0.81 | DDT (0.33) | DDTNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008021388-A1 | HETEROARYL DERIVATIVES AS CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2008-02-21 | — | — | WO | disclosed |